{ }
001122334455554433221100
001122334455554433221100

Pfizer appoints Chris Boshoff as new research and development chief

Pfizer has appointed Chris Boshoff as its new chief of research and development, effective January 1. Boshoff, who previously led the company"s cancer research and marketing, takes over from Mikael Dolsten, who stepped down after over 15 years. This leadership change comes amid pressure from activist investor Starboard and a decline in sales of Pfizer"s COVID-19 vaccine and antiviral Paxlovid, prompting a cost-cutting initiative.

Pfizer expands collaboration with Flagship startups for new drug discoveries

Pfizer has expanded its collaboration with Flagship Pioneering by partnering with two more startups, Montai Therapeutics and Ampersand Biomedicines, to develop drug candidates for lung cancer and obesity, respectively. Under the existing alliance, Pfizer will fund R&D and has the option to license the programs. This initiative aims to help Pfizer discover up to 10 new drug candidates while providing financial support to Flagship"s startups during challenging funding conditions.

endometriosis treatment market projected to reach 3.1 billion by 2034

The endometriosis treatment market is projected to grow from USD 1.4 billion in 2023 to USD 3.1 billion by 2034, driven by increasing awareness and advancements in treatment options. Key trends include the rise of non-hormonal therapies and personalized medicine, while challenges such as high costs and limited access persist, particularly in developing regions. The competitive landscape features major players like AbbVie and Pfizer, alongside emerging companies innovating to meet unmet needs.

pharmaceutical industry struggles to improve access to medicine in low-income countries

Pharmaceutical companies are increasingly focusing on access to medicines in low-income countries, with Novartis leading the way by integrating access plans into 96% of its late-stage drug projects. However, many companies still prioritize the US market, resulting in limited availability of essential medicines globally. Roche aims to double patient treatment numbers in low-income regions by 2026, yet significant gaps in transparency and patient reach persist across the industry.

global hashimoto thyroiditis market projected to reach 12.6 billion by 2033

The global Hashimoto"s thyroiditis market is projected to grow from $8.3 billion in 2023 to $12.6 billion by 2033, with a CAGR of 4.26%. North America is expected to dominate the market, while Asia-Pacific will experience the fastest growth due to rising healthcare awareness and improved infrastructure. The tablet segment will hold the largest market share, driven by convenience and patient compliance.

regenerative medicine market projected to reach 349 billion by 2033

The global regenerative medicine market is projected to grow from USD 31.90 billion in 2023 to USD 349.93 billion by 2033, with a CAGR of 27.06%. Cell therapy leads in market share, while musculoskeletal conditions are expected to grow the fastest. North America dominates the market due to advanced healthcare infrastructure and increased funding for research and development.

global patient-centric healthcare applications market projected to reach 58.72 billion by 2033

The global patient-centric healthcare applications market is projected to grow from $11.90 billion in 2023 to $58.72 billion by 2033, with a CAGR of 17.31%. North America is expected to dominate the market, while the Asia-Pacific region will experience the fastest growth. Key drivers include increased patient convenience and the rapid expansion of telemedicine, despite challenges related to security and privacy concerns.

ynthetic lethality drugs market projected to reach 5.3 billion by 2033

The global market for synthetic lethality drugs and targets is projected to grow from $1.3 billion in 2023 to over $5.3 billion by 2033, with a CAGR of 15.09%. North America is expected to dominate the market due to advances in genetic science and rising cancer rates, while the Asia-Pacific region is anticipated to experience the fastest growth. Key players include Pfizer, AbbVie, and AstraZeneca, with increasing investments in biotechnology and personalized medicine driving innovation in cancer treatment.

impact of robert f kennedy jr on us healthcare sector uncertainty

Robert F. Kennedy Jr."s nomination as secretary of health has caused healthcare stocks to drop, particularly affecting vaccine manufacturers like Moderna and Pfizer. Analysts express uncertainty about his potential impact on the sector, especially regarding vaccine policies and obesity treatments, while noting that large-cap stocks may have room for future growth. Kennedy"s views on drug pricing and oversight of Medicare and Medicaid could also reshape negotiations with pharmaceutical companies.

global consumer health market projected to reach over 713 billion by 2033

The global consumer healthcare market is segmented by product types, including OTC pharmaceuticals, personal care products, and dietary supplements, with offline distribution channels expected to dominate. North America is projected to lead the market due to rising awareness of wellness products, while Asia Pacific is anticipated to grow rapidly, driven by increasing disposable incomes and a large elderly population. Key players include Johnson & Johnson, Procter and Gamble, and Pfizer, among others, with ongoing developments enhancing market dynamics.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.